50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Myeloma Therapy: Phase III Trials

Monday, December 8, 2008: 3:30 PM-5:30 PM

Halls B and C (Moscone Center)

Moderators:

Paul Richardson, MD and S. Vincent Rajkumar, MD

3:30 PM

Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study

P. Wijermans¹, M. Schaafsma², Y. van Norden³^*, R. Ammerlaan⁴^*, S. Wittebol⁵^*, H. Sinnige⁶^*, Sonja Zweegman⁷, M. van Marwijk Kooi⁸^*, R. Van der Griend⁹^*, H. Lokhorst¹⁰ and P. Sonneveld¹¹

¹Haga Hospital, The Hague, Netherlands
²Dept of Hematology, Medisch Spectrum Twente, Enschede, Netherlands
³Dept of Trials and Statistics, HOVON, Erasmus MC, Rotterdam, Netherlands
⁴Dept. of trials and statistics, HOVON, Erasmus MC, Rotterdam, Netherlands
⁵Dept of Haematology,, Meander Medical Center Amersfoort, Amersfoort, Netherlands
⁶Dept of Hematology, Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands
⁷Department of Hematology, VU University Medical Center, Amsterdam, Netherlands
⁸Dept of Hematology, Isala clinics, Zwolle, Netherlands
⁹Dept. of Internal Medicine, Diakonessenhuis, Utrecht, Netherlands
¹⁰Hematology, University Medical Center Utrecht, Utrecht, Netherlands
¹¹Dept of Hematology, Erasmus Medical Center Rotterdam

3:45 PM

650

Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma

Jesus F San Miguel¹, Rudolf Schlag²^*, Nuriet K Khuageva³^*, Meletios A Dimopoulos⁴, Ofer Shpilberg⁵^*, Martin H Kropff⁶, Ivan Spicka⁷^*, Maria Teresa Petrucci⁸, Antonio Palumbo⁹, Olga S Samoilova¹⁰^*, Anna Dmoszynska¹¹^*, Kudrat M Abdulkadyrov¹²^*, Rik Schots¹³^*, Bin Jiang¹⁴^*, Maria-Victoria Mateos¹⁵^*, Kenneth C Anderson¹⁶, Dixie-Lee Esseltine¹⁷, Kevin Liu¹⁸^*, Andrew Cakana¹⁹, Helgi van de Velde²⁰^* and Paul Richardson²¹

¹Hospital Universitario Salamanca. CIC, IBMCC (USAL-CSIC), Salamanca, Spain
²Praxis for Hematology and Oncology, Wurzburg, Germany
³Hematology Department, SP Botkin Moscow City Clinical Hospital, Moscow, Russia
⁴Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
⁵Rabin Medical Center, Petah-Tiqva, Israel
⁶University of Munster, Munster, Germany
⁷1st Dept. of Int. Med, Charles Univ. Praha, Prague, Czech Republic
⁸University La Sapienza, Roma, Italy
⁹Divisione di Ematologia dell'Università di Torino, A.O.U. San Giovanni Battista, Torino, Italy
¹⁰Nizhnii Novgorod region Clinical Hospital, Russia
¹¹Medical University Lublin, Lublin, Poland
¹²St Petersburg Clinical Research Institute of Hematology & Transfusiology, Russia
¹³Myeloma Study Group, Belgian Hematological Society, Brussels, Belgium
¹⁴People's Hospital, Peking University, China
¹⁵Haematology, Hospital Universitario Salamanca, Salamanca, Spain
¹⁶Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹⁷Millennium Pharmaceuticals: The Takeda Oncology Company, Cambridge, MA
¹⁸Johnson & Johnson Pharmaceuticals Research & Development, Raritan, NJ
¹⁹Dept. of Clinical R&D Oncology, Johnson & Johnson Pharmaceuticals Research & Development, Beerse, Belgium
²⁰Johnson & Johnson Pharmaceuticals Research & Development, Beerse, Belgium
²¹Dana-Farber Cancer Institute, Boston, MA

4:00 PM

651

Bortezomib (Velcade)-Melphalan-Prednisone (VMP) Versus Velcade-Thalidomide-Prednisone (VTP) in Elderly Untreated Multiple Myeloma Patients: Which Is the Best Partner for Velcade: An Alkylating or An Immunomodulator Agent?

Maria-Victoria Mateos¹^*, Albert Oriol²^*, Joaquín Martínez³^*, Mª Teresa Cibeira⁴^*, Raquel de Paz³^*, Mª José Terol³^*, José García-Laraña³^*, Enrique Bengoechea³^*, Rafael Martínez³^*, Alejandro Martin³^*, Felipe de Arriba³^*, Luis Palomera³^*, José Hernández³^*, Jose-Luis Bello⁵^*, María-Luisa Martín³^*, Yolanda González³^*, Joan Blade, MD³, Juan José Lahuerta³^* and J.F San Miguel, MD, PhD⁶

¹University Hospital of Salamanca, Salamanca, Spain
²Hospital Germans Trials i Pujol, Badalona, Spain
³PETHEMA/Spanish Myeloma Group
⁴Hospital Clinic i Provincial de Barcelona, Barcelona, Spain
⁵Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
⁶University Hospital of Salamanca, PETHEMA/Spanish Myeloma Group, Salamanca, Spain

4:15 PM

652

A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients

Antonio Palumbo, MD¹, Sara Bringhen, MD¹^*, Davide Rossi, MD², Valeria Magarotto, MD¹^*, Francesco Di Raimondo, MD²^*, Roberto Ria, MD²^*, Massimo Offidani, MD²^*, Chiara Nozzoli, MD²^*, Francesca Patriarca³^*, Vincenzo Callea, MD²^*, Giulia Benevolo, MD²^*, Roberto Marasca, MD²^*, Tommasina Guglielmelli, MD²^*, Manuela Rizzo, MD²^*, Mariella Grasso, MD²^*, Maria Teresa Petrucci, MD²^*, Paola Omedè, PhD¹^*, Gianluca Gaidano, MD²^* and Mario Boccadoro, MD¹^*

¹Divisione di Ematologia dell'Università di Torino, A.O.U. San Giovanni Battista, Torino, Italy
²Italian Multiple Myeloma Network, GIMEMA, Italy
³Clinica Ematologica DIRM AOUD, Udine, Italy

4:30 PM

653

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

P. Sonneveld¹, B. van der Holt²^*, I. G.H. Schmidt-Wolf³^*, U. Bertsch⁴^*, L. el Jarari²^*, Hans-Jürgen Salwender³^*, S. Zweegman⁵, E. Vellenga⁵^*, J. Schubert³^*, I. W. Blau³^*, GSK Jie⁵^*, B. Beverloo⁵^*, A. Jauch⁴^*, D. Hose⁴^*, R. Schaafsma⁵^*, M. J. Kersten⁵^*, M. Delforge⁶^*, O. de Weerdt⁵^*, R. van der Griend⁵^*, P. W. Wijermans⁵^*, Hans Martin³^*, H. van der Velde⁷^*, Henk M. Lokhorst⁵^* and H. Goldschmidt⁴^*

¹HOVON and Erasmus MC, Rotterdam, Netherlands
²HOVON Data Center, Netherlands
³GMMG, Germany
⁴University of Heidelberg, GMMG, Germany
⁵HOVON, Netherlands
⁶HOVON, Belgium
⁷Johnson&Johnson, Belgium

4:45 PM

654

Thalidomide/Dexamethasone (TD) Vs. Bortezomib(Velcade®)/Thalidomide / Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade® As Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Younger Patients with Multiple Myeloma (MM): First Results of a Prospective Phase III PETHEMA/Gem Trial

Laura Rosinol¹^*, Mª Teresa Cibeira¹^*, Joaquin Martinez²^*, Maria Victoria Mateos²^*, Mª José Terol²^*, Javier de la Rubia²^*, Luis Palomera²^*, Felipe de Arriba²^*, Albert Oriol²^*, Adrian Alegre², Juan Besalduch², Raquel de Paz²^*, José Garcia-Laraña²^*, Joaquín Díaz-Mediavilla²^*, Anna Sureda²^*, Juan José Lahuerta²^*, J.F. San Miguel² and Joan Blade¹

¹Hematology, Hospital Clinic i Provincial, Barcelona, Spain
²PETHEMA/Spanish Myeloma Group, Spain

5:00 PM

655

Improved Survival of Patients with Multiple Myeloma after the Introduction of Novel Agents and the Applicability of the International Staging System (ISS) An Analysis of the Greek Myeloma Study Group (GMSG)

Efstathios Kastritis¹^*, Konstantinos Zervas¹^*, Argiris Symeonidis¹^*, Evangelos Terpos¹^*, Sossana Delimpassi¹^*, Nicolaos Anagnostopoulos¹^*, Evridiki Michali¹^*, Athanasios Zomas¹^*, Irini Katodritou¹^*, Dimitra Gika¹^*, Anastasia Pouli¹^*, Dimitrios Christoulas¹^*, Maria Roussou¹^*, Theofanis Economopoulos¹^* and Meletios A Dimopoulos²^*

¹Greek Myeloma Study Group, Greece
²Greek Myeloma Study Group, Athens, Greece

5:15 PM

656

Maintenance Thalidomide May Improve Progression Free but Not Overall Survival; Results from the Myeloma IX Maintenance Randomisation

Gareth J Morgan, MD, PhD¹, Graham H Jackson²^*, Faith E Davies, MD³^*, Mark T Drayson⁴^*, Roger G Owen⁵, Walter M Gregory⁶^*, Dena C Cohen⁶^*, Alex J. Szubert⁶^*, Susan E Bell⁶^*, Fiona Ross⁷^* and James A Child⁶^*

¹Section of Haemato-Oncology, The Institute of Cancer Research, London, United Kingdom
²University of Newcastle
³Section of Haemato-Oncology, Institute of Cancer Research, London, United Kingdom
⁴University Of Birmingham, Birmingham, United Kingdom
⁵United Leeds Teaching Hospitals
⁶University of Leeds
⁷Wessex Regional Cytogenetic Laboratory

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

653.O2.8 Myeloma Therapy: Phase III Trials